ZYXI News Alert Zynex Inc (ZYXI) 0.1402 09/28/2014 13:04:25

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Zynex Inc (ZYXI) 0.1402 $ZYXI

Zynex Announces Second Quarter 2014 Results
Marketwire - Thu Sep 25, 7:01AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today its unaudited financial results for the three and six months ended June 30, 2014.

Zynex Reschedules Second Quarter 2014 Earnings Release and Webcast to September 25, 2014
Marketwire - Wed Sep 17, 5:34PM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today the date for the Company's second quarter investor webcast has been rescheduled to Thursday, September 25th at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time.

Zynex Schedules Second Quarter 2014 Earnings Release and Webcast
Marketwire - Wed Sep 10, 2:31PM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host the Company's second quarter investor webcast on Thursday, September 18th at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time.

Zynex Announces Brian Alleman as Chief Financial Officer
Marketwire - Mon Jul 21, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today the appointment of Brian Alleman as its new chief financial officer.

Zynex Achieves Compound Pharmacy License Approval in 36 States
Marketwire - Tue Jul 15, 7:03AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it has attained compound pharmacy licensing approval in seventeen additional states bringing the total to thirty-six approvals.

Zynex Appoints Director of Business Development
Marketwire - Wed Jun 25, 7:02AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy, announced the hiring of Steve Siefring as Director of Business Development. Mr. Seifring will be responsible for driving sales activities in the electrotherapy and compound pharmacy business, reporting to Robert Bird, Vice President of Sales in the US.

Zynex Announces 2013 Year End Results
Marketwire - Thu Mar 27, 7:02AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today its year end 2013 financial results.

Zynex Schedules Year End 2013 Earnings Conference Call and Webcast
Marketwire - Thu Mar 20, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host an investor webcast on Thursday, March 27, 2014 at 11:00 a.m. ET -- 9:00 a.m. MT -- to discuss the Company's year end 2013 results.

Zynex Non-Sterile Compound Pharmacy Attains Licensing in 19 States
Marketwire - Mon Mar 03, 7:01AM CST
Zynex, Inc. (OTCQB: ZYXI), a medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that its subsidiary Zynex Medical, recently received its 19th state license for its non-sterile compound pharmacy.

Zynex Expands Electrotherapy Product Sales Channel
Marketwire - Tue Feb 11, 7:02AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnostics announces that it signed a strategic sales and marketing agreement with Total Care Marketing, LLC to sell its primary electrotherapy device, the NexWave, through Total Care Marketing's sales organization.

Zynex Receives Roszdravnadzor (Russian Equivalent of FDA) Clearance to Market Neuromove(TM) Stroke Recovery Device and NexWave(TM) Electrotherapy Device in Russia
Marketwire - Thu Feb 06, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnosis, announced today that Russia's Federal Service on Surveillance in Healthcare (Roszdravnadzor) has granted clearance to market its NeuroMove(TM) stroke recovery device and NexWave(TM) electrotherapy device.

ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.

Zynex Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its second quarter 2013 financial results.

Zynex Schedules Second Quarter 2013 Earnings Conference Call and Webcast
Marketwire - Thu Aug 01, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it will host an investor webcast, Thursday, August 8, 2013 at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time to discuss the Company's second quarter 2013 results.

Zynex Signs Strategic Agreement With Advanced Brain Monitoring, Expands Presence in Sleep Diagnostic Market
Marketwire - Mon Jul 22, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnostics and cardiac monitoring, announces that it signed a strategic sales, marketing and distribution agreement with California based Advanced Brain Monitoring.

The Neuromodulation Devices Market - Rising Numbers For Cases of Alzheimer's, Epilepsy, and Parkinson's Disease Leading to High Demand for Non-Invasive Treatments
M2 - Thu Jul 18, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s7pvwv/neuromodulation) has announced the addition of the "The Neuromodulation Devices Market" report to their offering. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S. Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation. The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.). For more information visit http://www.researchandmarkets.com/research/s7...modulation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Zynex Updates Financial Outlook for 2013
Marketwire - Fri Jul 12, 2:25PM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today the Company's updated financial outlook for the remainder of 2013.

Neuromodulation Market Research Report Forecasts to 2017 - Neuromodulation emerging as one of the fastest growing segments of the medical device market
M2 - Fri May 10, 6:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfbns4/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S. Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation. The key players in the neuromodulation devices market are: - Anm Adaptive Neuromodulation Gmbh - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed Gmbh - Cyberonics, Inc. - Endostim, Inc. - Enteromedics, Inc. - The Magstim Company Limited - Medtronic, Inc. - Neuronetics, Inc. - Neuropace, Inc. - Neurosigma, Inc. - Nevro Corporation - Rs Medical - Spinal Modulation, Inc. - St. Jude Medical - Synapse Biomedical, Inc. - Uroplasty, Inc. - Zynex, Inc. Scope of the Report The research report categorizes the global neuromodulation devices market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario. For more information visit http://www.researchandmarkets.com/research/wf...modulation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ZYXI Q1: Revenue and Margins Impacted - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 09, 7:16AM CDT
ZYXI Q1: Revenue and Margins Impacted

Zynex Announces First Quarter 2013 Financial Results
Marketwire - Wed May 08, 7:01AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its first quarter 2013 financial results.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

191 Schools Honored for Academic Growth Success

Updated Category News Views 44

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 59

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 12

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 120

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Boot Barn Holdings Inc's Updated Short Interest Trends

Updated Category News Views 216

Boot Barn Holdings Inc Short Interest Overview Boot Barn Holdings Inc (NYSE: BOOT) recently reported a decrease in its short interest as a percentage of the float, showing a 3.28% drop since the last report. Currently, there are approximately 3.45 million shares sold short, representing 15.33% of all the regular shares available for trading. Based on recent trading...

Continue Reading
Kura Oncology's Inducement Grants: Enhancing Employment Opportunities

Updated Category News Views 138

Kura Oncology's New Inducement Grants for Employees Kura Oncology, Inc., a prominent clinical-stage biopharmaceutical company, has recently made headlines with its innovative approach to employee engagements. This dynamic company is dedicated to the advancement of precision medicines that promise better treatments for cancer patients. To strengthen its workforce, Kura...

Continue Reading
Star Power and Dark History Fuel 'Hell's Half-Acre'

Updated Category News Views 70

A Gripping True Crime Tale Hits the Screen Does the open prairie of the 1870s Kansas and a family of killers strike a chill down your spine? If not, just wait until you get an eyeful of 'Hell's Half-Acre,' a film delving into America's first serial killing 'family.' Nicholas Nicastro, not one to shun bold storytelling, is the power wheel behind this upcoming...

Continue Reading
The Block Unveils Campus: A New Era in Crypto Education

Updated Category News Views 371

The Block Unveils Campus: A Revolutionary Education Platform The Block has unveiled its latest initiative, Campus by The Block, a comprehensive education and certification platform tailored specifically for the crypto industry. This innovative platform was introduced during The Block's inaugural global conference, highlighting its commitment to overcoming the challenges...

Continue Reading
Makino Milling Seeks Modifications to Nidec's Takeover Proposal

Updated Category News Views 825

Makino Milling Requests Changes to Nidec's Bid In a recent statement, Japanese machine tool manufacturer Makino Milling Machine has actively engaged with Nidec regarding an unsolicited takeover bid. This interaction highlights the ongoing dynamics within the industrial machinery sector and reflects the strategic decisions being made by companies in Japan. Details of the...

Continue Reading